GSK plc's Schedule 13D Filing for CureVac N.V.

GSK plc filed a Schedule 13D with the SEC regarding its ownership of common shares in CureVac N.V. The filing indicates that GSK, through its wholly-owned subsidiary Glaxo Group Limited (GGL), owns 16,591,937 common shares, representing 74% of the outstanding shares. GSK acquired these shares for investment purposes and not to influence the control of CureVac. The filing also discloses a Tender and Support Agreement between GGL and BioNTech SE, dated August 7, 2025, which includes provisions for GGL to tender its shares in an exchange offer by BioNTech. The agreement also includes voting commitments and restrictions on GGL's actions regarding CureVac. The filing supersedes a previously filed Schedule 13G and provides detailed information on the transactions and agreements related to GSK's ownership of CureVac shares.